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Abstract
Background: Asthmatic chronic rhinosinusitis with nasal polyps (aCRSwNP) is a common disruptive eosinophilic disease
without effective medical treatment. Therefore, we sought to identify gene expression changes, particularly those occurring
early, in aCRSwNP. To highlight expression changes associated with eosinophilic epithelial inflammation, we further
compared the changes in aCRSwNP with those in a second eosinophilic epithelial disease, atopic dermatitis (AD), which is
also closely related to asthma.
Methods/Principal Findings: Genome-wide mRNA levels measured by exon array in both nasosinus inflamed mucosa and
adjacent polyp from 11 aCRSwNP patients were compared to those in nasosinus tissue from 17 normal or rhinitis subjects
without polyps. Differential expression of selected genes was confirmed by qRT-PCR or immunoassay, and transcription
changes common to AD were identified. Comparison of aCRSwNP inflamed mucosa and polyp to normal/rhinitis tissue
identified 447 differentially transcribed genes at $2 fold-change and adjusted p-value,0.05. These included increased
transcription of chemokines localized to chromosome 17q11.2 (CCL13, CCL2, CCL8, and CCL11) that favor eosinophil and
monocyte chemotaxis and chemokines (CCL18, CCL22, and CXCL13) that alternatively-activated monocyte-derived cells
have been shown to produce. Additional transcription changes likely associated with Th2-like eosinophilic inflammation
were prominent and included increased IL1RL1 (IL33 receptor) and EMR1&3 and decreased CRISP2&3. A down-regulated
PDGFB-centric network involving several smooth muscle-associated genes was also implicated. Genes at 17q11.2, genes
associated with alternative activation or smooth muscle, and the IL1RL1 gene were also differentially transcribed in AD.
Conclusions/Significance: Our data implicate several genes or gene sets in aCRSwNP and eosinophilic epithelial
inflammation, some that likely act in the earlier stages of inflammation. The identified gene expression changes provide
additional diagnostic and therapeutic targets for aCRSwNP and other eosinophilic epithelial diseases.
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Introduction
Chronic rhinosinusitis (CRS) is one of the most prevalent
chronic diseases in the United States, afflicting about 10% of the
population [1,2]. Coexisting pathologies often include asthma and
nasal polyps. Because there are not FDA-approved pharmaceu-
tical interventions to treat CRS, nasal polyposis frequently leads to
surgical intervention to clear the nasosinus passages, and repeat
endoscopic sinus surgery is often required. Asthma is equally
prominent and socioeconomically detrimental.
Asthmatic CRS (aCRS), and other allergic diseases such as
atopic dermatitis (AD), which has an asthma comorbidity of about
30%, are generally associated with Th2-like eosinophilic inflam-
mation [3,4,5]. As end-stage effector cells, eosinophils contribute
to epithelial damage [6]; although, recent studies suggest a role for
eosinophils in earlier stages of allergic disease [7,8,9]. Resident
epithelial and mast cells and other tissue-infiltrating cell types,
particularly dendritic and T helper cells, also contribute to
eosinophilic inflammation. Gene expression changes preceding
chronic eosinophilic inflammation are not fully understood, but
intervening early in an eosinophilic inflammatory response to
minimize downstream inflammation is appealing.
High-density oligonucleotide arrays, often referred to as
microarrays, are a popular screening method for gene transcrip-
tion changes associated with disease pathology. A literature search
for articles involving microarray analysis of sinusitis or nasal polyps
identified 13 relevant articles; three included large-scale gene
transcription analysis of tissue from patients with CRS, asthma,
and nasal polyps [10,11,12]. However, several discordant gene
transcription changes were reported by Liu et al. [10] compared to
Stankovic et al. [11]. Also, none of these studies sought to analyze
gene transcription changes in adjacent inflamed nasosinus mucosa,
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more pronounced inflammation. Furthermore, accessibility to
well-preserved human asthmatic lung tissue for gene expression
analyses is limited, with only one published genome-wide
transcription study identified [13]. Interestingly, a recent report
indicated that nasal tissue could be a reasonable surrogate for lung
tissue [14]. Therefore, we studied both nasosinus polyps and
adjacent inflamed mucosa from young aCRSwNP subjects to
identify gene expression changes, particularly early changes, in the
inflammatory process of this and other eosinophilic conditions.
Materials and Methods
Research Subjects and Tissue Collection
Ethics Statement: All specimens were collected at the Mayo
Clinic - Rochester and after obtaining informed written consent
under a Mayo Clinic - Rochester Institutional Review Board-
approved protocol. Twelve aCRS subjects (11 with nasal polyps)
provided inflamed nasosinus mucosa (11 samples) and adjacent
polyp (10 samples) or a small mixed mucosa and polyp specimen (1
sample). Inflamed mucosa or polyp was from the middle meatus or
anterior ethmoid cavity. Inclusion criteria for aCRS subjects
included two or more of the following symptoms for .12 weeks:
nasal obstruction, nasal discharge, hyposmia, and nasal cavity
purulence. Computed tomography (CT) confirmation of basement
membrane thickening, endoscopic assessment of nasosinus pas-
sages, and concurrent physician-diagnosed asthma together with
objective evidence for airway hyperreactivity or airway reversibil-
ity were also required. Among the normal or rhinitis subjects
without nasal polyps (n=17), 4 had physician-diagnosed allergic
rhinitis (AR), 2 had suspected AR, 1 had suspected vasomotor
rhinitis, and 10 had no signs of nasosinus disease, allergy, or atopy.
Normal and rhinitis tissue was collected from the inferior turbinate
or uncinate process. All 4 AR subjects chose to donate tissue
outside of their known allergy season(s). General exclusion criteria
included smoking, history of immunodeficiency or cystic fibrosis,
pregnancy or lactation, overt bacterial or viral infection, and use of
antibiotics, systemic glucocorticoids, or allergy immunotherapy 7
days, 3 months, or 1 year, respectively, before tissue donation.
Rhinitis or aCRS subjects also stopped intranasal and oral
medications $4 days and inhaled medications $1 day before
tissue donation. All subjects refrained from using non-prescribed
medications $4 days before tissue donation. Pre-operative
intranasal preparation included topical 4% cocaine and injected
1% lidocaine with 1/100,000 epinephrine. Tissue was immedi-
ately placed in 4 mL of room temperature RNAlater for 2 minutes
with mixing, transported on ice, held overnight at 4uC, and placed
at 220uC until total RNA isolation.
Total RNA Isolation
After removal from RNAlater, each specimen was frozen in
liquid nitrogen, placed in ice-cold TRIzol (Invitrogen, Carlsbad,
CA), and immediately shattered and homogenized with a Polytron
homogenizer (Brinkmann Instruments, Westbury, NY). Total
RNA was isolated according to the manufacturer’s protocol for
TRIzol and further purified using the RNeasy Mini kit (Qiagen,
Valencia, CA). Purified total RNA was supplied to the Mayo
Microarray Core facility, assessed for integrity using the Agilent
Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA), and used
for exon array analyses. To compensate for potential variability
among exon array analyses, total RNA was isolated from and
analyzed in batches comprised of different specimen types. Excess
total RNA was stored at 280uC.
Exon Array Hybridization
Following the Affymetrix GeneChipH Whole Transcript Sense
Target Labeling Assay (Affymetrix, Santa Clara, CA), total RNA
was depleted of ribosomal RNA and converted into double-
stranded cDNA using random hexamers tagged with a T7
promoter sequence. This cDNA was used as template for T7
RNA Polymerase amplification into antisense cRNA. The cRNA
was converted into single-stranded sense DNA with incorportated
dUTP, fragmented at the dUTP sites, and end-labeled with biotin.
Hybridizations to Affymetrix GeneChipH Human Exon 1.0 ST
Arrays were performed overnight at 45uC. Arrays were washed,
stained with phycoerythrin-labeled streptavidin, and scanned in
the Affymetrix GeneChipH Scanner. The resulting image files
were analyzed using Affymetrix Microarray Suite 5.1 to generate
.CEL files containing the probe level intensities and the x, y
coordinates of each probe on the array.
Exon Array Data Analysis
The 39 exon array .CEL files (deposited at NCBI Gene
Expression Omnibus (GEO)) were imported using PartekH
Genomics Suite
TM software (Partek Incorporated, St. Louis,
MO) and normalized using default RMA settings. Transcript
expression levels were calculated using the well-established ‘‘core’’
set of exons for 21,980 distinct genes. Comparisons between
sample groups were performed using GeneSpring GX 9.0 software
(Silicon Genetics, Redwood City, CA). Molecular network
analyses of the identified differentially transcribed genes used
Ingenuity Pathways Analysis software (Ingenuity Systems, Moun-
tain View, CA).
Quantitative RT-PCR
Excess total RNAs stored at 280uC and from the same
preparations used to generate exon array data were used for qRT-
PCR. Reverse transcription used 2 mg of total RNA and the
SuperScript VILO cDNA synthesis kit (Invitrogen). Resulting
cDNA samples were used as PCR template in conjunction with
SYBR GreenER qPCR Supermix (Invitrogen). All PCR primer
pairs were from SABiosciences (Frederick, MD). Standard curves
for housekeeping genes (B2M, ACTB, and GAPDH) and target
genes (CCL13, CCL18, CRISP3, EMR3, and IL1RL1) were
generated using eight two-fold dilutions of cDNA produced from a
pooled sample of total RNA from two normal and one aCRSwNP
polyp specimens. Individual cDNA samples were used in triplicate
PCRs over a 10-fold dilution range and these were performed
twice. Threshold cycle numbers for the various PCRs were
compared to the appropriate standard curve to calculate a relative
quantity of starting cDNA for each housekeeping gene and each
target gene within each individual sample tested. Ratios of target
gene quantity to each of the three housekeeping gene quantities for
each sample were subsequently calculated. Because using data for
each of the individual housekeeping genes provided proportionally
similar ratio results, an average target gene to housekeeping genes
ratio was calculated for each sample tested.
Charcot-Leyden Crystal (CLC) protein Competitive
Radioimmunoprecipitation Assay
Nasal lavage fluid or secretions were collected under Mayo IRB-
approved protocols from normal, AR, and CRS subjects distinct
from those donating nasosinus tissue for exon array analyses.
Recombinant human CLC protein (kindly provided by SJ
Ackerman, The University of Illinois at Chicago) labeled with
125I was mixed with 2-fold dilutions of unlabeled, purified
recombinant human CLC protein, for standard curve generation,
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antibody (generated in the Mayo Allergic Diseases Research
Laboratory) overnight at 4uC. Burro anti-rabbit IgG antibody was
added and the mixture was left at room temperature for 3 hr and
then centrifuged at 10006g for 15 min. Supernatant was carefully
drained away for 1 min and the immunoprecipitated pellet was
counted for radioactivity.
Comparison of Atopic Dermatitis (AD) and aCRSwNP
Array Data
AD array data sets from Olsson et al. (GSE6012 NCBI Gene
Expression Omnibus (GEO); lesional AD skin, n=10, and normal
skin, n=10) [15] and from our group (GSE5667 NCBI GEO;
minimally lesional AD skin, n=6, and nearby visibly nonlesional
AD skin, n=6, and normal skin, n=5) [16] were imported
separately into GeneSpring GX 9.0. After an initial low stringency
comparison between AD and normal samples within each data set
(fold change (Fc)$1.4 and unpaired nonparametric Mann-
Whitney U test, p#0.22), subsequent analyses for differentially
transcribed genes between AD and normal samples at Fc$2.0 and
adjusted p-value#0.1 (unpaired nonparametric test with Benja-
mini-Hochberg False Discovery Rate adjustment) were performed.
A union set (i.e. a combined list) from the two AD to normal skin
comparisons was generated, and the intersection of this union set
with the list of differentially transcribed genes from the comparison
of aCRSwNP to normal/rhinitis nasosinus tissue (Fc$2.0 and
adjusted p-value#0.05) was generated based on identical Gene
Symbols or RefSeq Transcript IDs using Microsoft Office Access
2003 software to identify the differentially transcribed genes
common to AD and aCRSwNP.
Immunohistochemical Staining for CD11c
CD11c staining was performed using mouse anti-human
CD11c (BD Pharmingen, San Diego, CA) and the UltraVision
LP Detection kit (Lab Vision Corp., Fremont, CA) according to
the manufacturer’s instructions on frozen nasosinus tissue sections.
Results
Demographic and clinical data for the 12 aCRS and the 17
normal or rhinitis subjects donating tissue for exon array analyses
are shown in Table S1. Besides focusing on CRS patients with
concurrent asthma, most of whom also had nasal polyposis,
relatively young subjects (18 to 58 years old) were recruited to
focus on immune-related rather than potential age-related
nasosinus tissue changes. To assess the clinical categorization of
the various subjects’ specimens (i.e. normal, rhinitis, aCRS
inflamed mucosa, or aCRS polyp), data from the most
phenotypically distinct specimens, 9 clearcut aCRS nasal polyp
(aCRSp3 through aCRSp11) and 8 clearcut normal (N1 through
N8) specimens, were compared using a gene-level analysis of
,22,000 well-established genes. This preliminary comparison
identified 528 putative differentially-transcribed genes with
Fc.2.0 and adjusted p-value,0.05 (unpaired nonparametric test
with Benjamini-Hochberg False Discovery Rate adjustment).
These genes were then used to assess where the remaining
specimens fell in comparison (Figure 1). The normal and rhinitis
samples were grouped together relative to all but two of the aCRS
inflamed mucosa samples (aCRSm1 and aCRSm2). These two
samples had mixed heat map profiles (Figure 1), with some sections
similar to the normal and rhinitis samples and other sections more
like the other aCRS samples (both inflamed mucosa and polyp).
Interestingly, one of these samples (aCRSm2) was from the one
aCRS patient without nasal polyps.
Given the distinct transcript profile for most of the 22 aCRS
samples, this group of samples (designated aCRSwNP; 20 samples
of inflamed mucosa, polyp, or both from 11 aCRSwNP patients,
with the aCRSm1 and aCRSm2 samples excluded), was compared
to all of the normal and rhinitis samples (n=17). An analysis
considering only well-established genes identified 447 differential-
ly-transcribed genes (261 with increased transcription) at Fc.2.0
and adjusted p-value,0.05 (Table 1 and Table S2; to identify the
data for a particular gene in Table S2 use the ‘‘Find’’ function to
search using any Gene Symbol mentioned in this article, e.g.
‘‘CCL8’’ or ‘‘CRISP2’’). Notably, several genes in Table 1 and
Table S2 were also identified by Stankovic et al. in their aspirin-
sensitive aCRSwNP patients [11]. These included increased
transcription of periostin (POSTN) and DC-SIGN (CD209) and
Figure 1. Heat Map Profiles of the 39 Nasosinus Tissue
Specimens Analyzed by Exon Array. Each horizontal bar represents
1 of the 528 genes identified as differentially transcribed between
clearcut Normal samples (N1 to N8) and clearcut aCRS polyp samples
(aCRSp3 to aCRSp11). The bar color indicates the relative transcription
level from blue (low) through white to red (high). Inflamed mucosa
samples are indicated by ‘‘m’’, and aCRSm12 was a small sample of
mixed inflamed mucosa and polyp. The inflamed mucosa (m) and polyp
(p) aCRS samples with the same ending number are from the same
donor.
doi:10.1371/journal.pone.0011450.g001
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statherin (STATH), and prolactin-induced protein (PIP).
Transcription levels of five of the identified genes, which were
also among 221 genes identified as differentially transcribed when
comparing only aCRS inflamed mucosa (n=11; aCRSm1
through aCRSm11) to normal and rhinitis (n=17) exon array
data (data not shown), were assessed by qRT-PCR (Figure 2). In
agreement with the exon array data, CCL13, CCL18, EMR3, and
IL1RL1 transcription was increased while CRISP3 transcription
was decreased in inflamed mucosa and polyp tissue from
aCRSwNP subjects.
Because mRNA levels are not always directly proportional to
their corresponding protein levels, we utilized an immunoassay
available in our laboratory to assess CLC levels in nasal lavage
fluid or suction-collected secretions from a separate population of
CRS subjects. This showed significantly elevated CLC protein in
CRS specimens relative to nasal lavage fluids from normal controls
or AR subjects with active disease (Figure 3), similar to the
observed CLC mRNA increase in aCRSwNP (Table 1). We also
recently reported increased CCL18 protein levels in induced
sputum from asthmatic subjects [17], which is consistent with the
increased CCL18 transcription observed here in aCRSwNP.
Overall, comparisons with a similar array study of aspirin-sensitive
aCRSwNP [11] and several assays at both the mRNA and protein
levels support our gene-level exon array results.
Because molecular pathway or network analyses can identify
biologically relevant gene interactions that might be hidden when
considering only individual genes, Ingenuity Pathways Analysis
software was used to analyze the 447 differentially-transcribed
genes from the comparison between aCRSwNP and normal/
rhinitis samples. In general, the top canonical pathways included
those related to leukocyte extravasation, hepatic fibrosis, eicosa-
noid signaling, chemokine signaling, IL10 signaling, and the
complement system. The presumed inflammation-associated
networks involving NF-kB, Integrins, IL6, TGFb, and TNF family
members and Th2-associated networks involving IL4 and IL13
were among the non-canonical molecular networks identified. A
down-regulated PDGFB homodimer-centric network involving
several smooth muscle-related genes was also identified (Figure 4).
In parallel analyses, differentially transcribed genes in a second
eosinophilic inflammatory disease, AD, were compared to those in
aCRSwNP to identify common eosinophil-associated inflamma-
tory pathways, including those likely occurring early in the
inflammatory process [16]. Table 2 shows a list of 85 common
genes and their tentative functional groupings. Interestingly, nine
genes associated with smooth muscle, including several in the
PDGFB network implicated by our aCRSwNP data, also showed
decreased transcription in AD (Table 2, Group 1).
Discussion
Because aCRSwNP and other eosinophilic epithelial diseases
are prevalent and difficult to control, early and specifically-
targeted interventions against eosinophilic inflammation are
needed. Therefore, we gathered aCRSwNP array data and
compared it to other reported array data. Overall, we verified
the differential expression of several genes recently associated
with aspirin-sensitive aCRSwNP [11] and implicated several
other genes or gene sets in the earlier stages of eosinophilic
inflammation.
Assessing the validity of our exon array data at the entire gene
transcript level was an initial goal. Comparison to the recent
Stankovic et al. study [11], involving a patient population similar
to ours and using more anatomically matched normal control
Table 1. Top 10 over- and under-transcribed genes in asthmatic chronic rhinosinusitis with nasal polyps (aCRSwNP).
Transcript ID Fold Change p-value* gene_assignment
3718902 76.43 5.43E-15 NM_002988 // CCL18 // chemokine (C-C motif) ligand 18 // 17q11.2 // 6362
3862108 32.69 1.63E-13 NM_001828 // CLC // Charcot-Leyden crystal protein // 19q13.1 // 1178
3901361 31.53 1.82E-11 NM_001898 // CST1 // cystatin SN // 20p11.21 // 1469
3718204 14.01 1.30E-12 NM_005408 // CCL13 // chemokine (C-C motif) ligand 13 // 17q11.2 // 6357
2497082 8.82 1.91E-11 NM_016232 // IL1RL1 // interleukin 1 receptor-like 1 // 2q12 // 9173
3901387 8.34 3.19E-10 NM_001322 // CST2 // cystatin SA // 20p11.21 // 1470
3510066 7.89 1.19E-13 NM_006475 // POSTN // periostin, osteoblast specific factor // 13q13.3 // 10631
3818596 7.69 1.38E-10 NM_001974 // EMR1 // egf-like module containing, mucin-like, hormone receptor-like 1 // 19p13.3 // 2015
3852832 6.82 1.12E-11 NM_032571 // EMR3 // egf-like module containing, mucin-like, hormone receptor-like 3 // 19p13.1 // 84658
2940202 6.77 5.38E-13 NM_000129 // F13A1 // coagulation factor XIII, A1 polypeptide // 6p25.3-p24.3 // 2162
3063589 26.66 6.31E-07 NM_001185 // AZGP1 // alpha-2-glycoprotein 1, zinc // 7q22.1 // 563
2923270 26.99 9.77E-11 NM_002667 // PLN // phospholamban // 6q22.1 // 5350
2730173 27.32 1.08E-05 NM_003154 // STATH // statherin // 4q11–q13 // 6779
2489007 27.38 1.14E-10 NM_001615 // ACTG2 // actin, gamma 2, smooth muscle, enteric // 2p13.1 // 72
3728637 27.70 6.29E-09 NM_006151 // LPO // lactoperoxidase // 17q23.1 // 4025
2730431 210.25 3.79E-08 NM_152291 // MUC7 // mucin 7, secreted // 4q13–q21 // 4589
3028934 216.93 1.26E-09 NM_002652 // PIP // prolactin-induced protein // 7q34 // 5304
3444578 217.50 6.46E-06 NM_002723 // PRB4 // proline-rich protein BstNI subfamily 4 // 12p13.2 // 5545
2925013 218.67 1.73E-09 NM_001010905 // C6orf58 // chromosome 6 open reading frame 58 // 6q22.33 // 352999
2956563 228.15 3.85E-13 NM_006061 // CRISP3 // cysteine-rich secretory protein 3 // 6p12.3 // 10321
*unpaired nonparametric test with Benjamini-Hochberg False Discovery Rate adjustment.
doi:10.1371/journal.pone.0011450.t001
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specimens), provided confidence because differential expression of
several genes important in aspirin-sensitive aCRSwNP were also
identified in our data (decreased AZGP1, STATH, and PIP and
increased DC-SIGN (CD209) and POSTN; with increased
POSTN expression also being observed in eosinophilic esophagitis
(EE) [18]). Interestingly, these results were often opposite to those
of Liu et al., who reported increased transcription of AZGP1,
STATH, PIP, and CRISP3 [10]. The most apparent reason
for these differences may be the required use of intranasal
glucocorticoids for at least 1 month before tissue collection in the
Liu et al. study [10]. Our qRT-PCR results for CCL13, CCL18,
CRISP3, EMR3, and IL1RL1 (ST2) (Figure 2) and the increased
presence of CLC (Figure 3) and CCL18 [17] protein in separately
collected airway specimens from CRS or asthmatic patients, in
accordance with their increased mRNA levels in our aCRSwNP
patients, further support the validity of our exon array data.
Notably, none of the five qRT-PCR-confirmed genes (Figure 2)
have been specifically associated with aCRSwNP before and their
differential transcription in inflamed mucosa potentially suggests
their involvement in the earlier stages of inflammation.
Transcript levels of the five qRT-PCR-confirmed genes in
aCRSwNP were relatively distinct when compared to the AR
samples (Figure 2). However, the mild disease of the AR tissue
donors (because they chose to undergo nasosinus surgery outside
Figure 2. Relative Transcription Levels of Selected Genes by
qRT-PCR. The ratio of the relative quantity of the designated target
gene (CCL13, CCL18, CRISP3, EMR3, or IL1RL1) to that of one of three
housekeeping genes (B2M, ACTB, or GAPDH) was determined. Because
each of the three housekeeping genes gave proportionally similar ratio
results, an average target gene to housekeeping genes ratio was
calculated and plotted for each of the individual samples indicated
along the x-axis [normal (n=8), AR (n=3), aCRS without nasal polyps
(n=1; aCRSm2), and aCRSwNP (n=10, including both inflamed mucosa
and polyp tissue samples from each of these 10 subjects)].
doi:10.1371/journal.pone.0011450.g002
Figure 3. Charcot-Leyden Crystal (CLC) Protein Levels in
Various Nasosinus Lavage Fluids or Secretions. Nasal lavage
fluid was collected from subjects distinct from those donating tissue for
exon array analyses and with no history of nasosinus disease (n=9,
Normal), with active allergic rhinitis (n=9, AR), and with asthmatic CRS
(n=7, CRS). Nasal secretions were also collected by gentle suction from
additional subjects diagnosed with CRS (n=12, CRS(secretions)). Each
sample was assayed for CLC protein by a competitive radioimmuno-
precipitation assay.
doi:10.1371/journal.pone.0011450.g003
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between aCRSwNP and AR were caused by differences in disease
severity rather than disease-specific gene transcript profiles. Still, a
study of AR without and with nasal polyps indicated an association
of mammaglobin-1 and 33 other genes with nasal polyposis [19].
However, neither mammaglobin-1 nor a substantial majority of
the other 33 genes (only increases in prostaglandin D2 synthase
and cystatin S appeared common) were among the genes showing
differential transcription in our aCRSwNP samples. Thus, it
remains possible that gene transcript profiles unique or only
partially overlapping between AR and aCRSwNP exist, with nasal
polyposis in these two diseases mediated by two separate
mechanisms.
While several other putative differentially transcribed genes or
gene sets identified here are likely of interest (e.g. cystatins,
osteopontin (SPP1), histamine H4 receptor, etc.; Table S2), we are
limiting our further discussion to gene sets that appear relevant to
the eosinophilic inflammation of aCRSwNP and other eosino-
philic epithelial diseases.
The most prominent class of up-regulated genes identified in
aCRSwNP appeared to be the chemokines (Table S2). The strong
eosinophil chemoattractants eotaxin-1 (CCL11), 22 (CCL24), and
23 (CCL26) (the latter also increased in AD (Table 2) and EE
[20]) were up-regulated. Several other up-regulated genes that are
adjacent to CCL11 at chromosome 17q11.2 included CCL13
(MCP4), CCL2 (MCP1), and CCL8 (MCP2); both CCL13 and
CCL2 were also up-regulated in AD skin (Table 2). Thus,
induction of this 17q11.2 gene cluster likely contributes strongly to
eosinophilic epithelial inflammation, and the 17q11.2 locus was
previously identified as a candidate gene region associated with
AD [21]. When analyzed for relevant molecular networks, the
increased transcription of most of these chemokines and some of
their receptors in aCRSwNP shows an association to NF-kB-
mediated regulation (Figure S1).
Both aCRSwNP and AD showed increased transcription of
CCL18 (PARC), CCL22 (MDC), and CXCL13. These are
notable because of their production from IL4- or IL13-
‘‘alternatively activated’’ members of the mononuclear phagocyte
system, which includes monocytes, macrophages, and dendritic
cells [22,23]. So-called inflammatory dendritic cells (also known
as inflammatory dendritic epidermal cells (IDECs)) likely
represent a prominent form of CD11c+ monocyte-derived
alternatively-activated dendritic cells in AD skin [24,25], and
an abundant CD11c+ cell population can also be observed in
CRS with nasal polyposis (Figure S2). Other cell types, such as
epithelial cells, may also produce these chemokines under these
conditions. CCL18 and CCL22 are associated with chemoattrac-
tion of Th2 cells, which further amplify eosinophilic inflamma-
tion. The CCL18 gene is also located near the eotaxin-1 and
MCP genes cluster at chromosome 17q11.2. Intriguingly, these
genes are substantially up-regulated 4 hours after allergen
inhalation challenge in Ascaris suum-sensitized monkeys with
marked post-challenge eosinophil lung infiltration [26], and
CCL18 and CCL13 appear to be up-regulated even in acute or
minimally lesional AD skin [27,16,25]. An alternative activation
profile is also observed in severe asthma exacerbations [28].
Thus, the 17q11.2 genes likely contribute relatively early to the
eosinophilic inflammatory response.
Figure 4. Molecular Network Implicating Platelet-Derived Growth Factor Beta Homodimer (PDGF BB) in aCRSwNP Pathology. The
genes showing reduced transcription in aCRSwNP (see Table S2) were analyzed using Ingenuity Pathways Analysis software, and this was the first-
most significant network identified. The intensity of green indicates the degree of reduced transcription, and the length of a line reflects the evidence
supporting the relationship between two genes – shorter lines indicating stronger literature support. The geometric shape associated with a gene
symbol indicates the gene product’s function. ADRA1A, alpha-1A-adrenergic receptor; CNN1, basic smooth muscle calponin 1; CYR61, cysteine-rich
angiogenic inducer 61; FHL1, four and a half LIM domains 1; GEM, GTP binding protein overexpressed in skeletal muscle; MYH11, smooth muscle
myosin heavy chain 11; MYOCD, myocardin; NEXN, nexilin (F actin binding protein); NR4A1, nuclear receptor subfamily 4, group A, member 1; NR4A2,
nuclear receptor subfamily 4, group A, member 2; SLCO1A2, solute carrier organic anion transporter family, member 1A2.
doi:10.1371/journal.pone.0011450.g004
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member of the IL1 family, although the IL33 gene is located on a
separate chromosome). This receptor-ligand pair may contribute
to both innate and acquired Alternaria-induced eosinophil
responses of the airways via Alternaria-induced IL33 release from
airway epithelial cells (H. Kouzaki & H. Kita, unpublished data)
and via expression of IL1RL1 directly by eosinophils and
indirectly by basophils, mast cells, dendritic cells, and Th2 cells
[29,30,31]. Increased IL1RL1 transcription is also observed in AD
(Table 2), and IL33 appears to be increased in AD skin and
anaphylactic responses [32]. IL33 amplification of IL13-induced
alternatively-activated macrophage polarization in asthma patients
has also recently been suggested [33]. Thus, the IL33-IL1RL1
interaction is likely a key contributor to both innate and acquired
mechanisms of eosinophilic inflammation in aCRSwNP.
Increased transcription of both EMR3 and EMR1 was observed
in our exon array data. These appear to be G protein-coupled
seven-transmembrane receptors, and among peripheral blood
leukocytes, EMR1 was expressed predominantly by eosinophils
[34]. The mucin-like domain of these molecules further suggests
that they contribute to eosinophil adhesion and activation.
Whether EMR3 and EMR1 transcription per eosinophil is
increased in aCRSwNP or the increased transcription reflects
elevated numbers of infiltrating eosinophils is unknown. Regard-
less, these receptors will likely help mediate eosinophil function
that contributes to disease pathology. In contrast to EMR3 and
EMR1, our exon array data showed decreased transcription of
CRISP3 and CRISP2. Although the function(s) of these molecules
is obscure, decreased transcription of CRISP3 is observed in EE
and associated with the presence of IL13 [20].
Table 2. Genes Showing Similar Differential Transcription in aCRSwNP and AD.
Gene Symbol RefSeq ID
Potential
Group* Gene Symbol RefSeq ID
Potential
Group Gene Symbol RefSeq ID
Potential
Group
Decreased Transcription
ACTG2** NM_001615 1 MYH11 NM_002474 1 PRKAA2 NM_006252
CNN1 NM_001299 1 MYRIP NM_015460 1 PRR4 NM_007244
DES NM_001927 1 NAP1L2 NM_021963 RNF128 NM_194463
FABP4*** NM_001442 NPY1R NM_000909 SORBS1 NM_015385
FHL1 NM_001449 1 OGN NM_033014 TAGLN NM_001001522 1
GPM6A NM_201592 PIP NM_002652 2 TSPAN6 NM_003270
LMOD1 NM_012134 1 PLN NM_002667 1
MSMB NM_138634 PRB4 NM_002723
Increased Transcription
ADAM8 NM_001109 2 GNA15 NM_002068 PIM2 NM_006875
ALOX15 NM_001140 GPR109B NM_006018 PTPRC NM_080922
ALOX5AP NM_001629 GPR44 NM_004778 5 RAC2 NM_002872
ARRB2 NM_004313 HRH4 NM_021624 5 RHOH NM_004310
CCL13 NM_005408 3 IFI30 NM_006332 S100A8 NM_002964
CCL18 NM_002988 3 IGFBP3 NM_001013398 S100A9 NM_002965
CCL2 NM_002982 3 IL1RL1 NM_016232 5 SAMSN1 NM_022136
CCL22 NM_002990 3 IL4R NM_000418 5 SELE NM_000450 6
CCL26 NM_006072 3 ITGAM NM_000632 6 SELPLG NM_003006 6
CCR1 NM_001295 3 KIAA1199 NM_018689 SLA NM_006748
CD1B NM_001764 4 LCP1 NM_002298 SLAMF8 NM_020125
CD1C NM_001763 4 LCP2 NM_005565 SLC7A8 NM_012244
CD1E NM_030893 4 LST1 NM_205837 SPON1 NM_006108
CD300A NM_007261 5 LTB NM_009588 SRGN NM_002727
CD52 NM_001803 MARCO NM_006770 SYK NM_003177
CLEC4A NM_194450 MMP9 NM_004994 2 TGFB1 NM_000660 3
CTSC NM_148170 2 MNDA NM_002432 TMEM156 NM_024943
CXCL13 NM_006419 3 MS4A4A NM_024021 5 TNC NM_002160
DOCK2 NM_004946 MXD1 NM_002357 TOP2A NM_001067
DOK2 NM_003974 NP NM_000270
FFAR2 NM_005306 PCSK1 NM_000439 2
FPR3 NM_002030 PCSK6 NM_138319 2
*1=muscle-related; 2=protease/protease-like; 3=chemokine or cytokine; 4=antigen presentation; 5=allergy-associated receptor; 6=cell adhesion.
**For information about any of the listed genes, go to the National Center of Biotechnology Information (NCBI) website and search using the gene’s Gene Symbol (e.g.
ACTG2) or RefSeq ID (e.g. NM_001615).
***Genes in bold showed similar and significant differential transcription in both of the atopic dermatitis data sets used.
doi:10.1371/journal.pone.0011450.t002
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epidermal differentiation complex at chromosome 1q21, in
epithelial cells from CRS patients with and without nasal polyps
was recently reported [35,36]. However, our analyses indicate
increased transcription of S1008A and S100A9 in whole tissue
from both aCRSwNP and AD patients (Table 2), and in a
proteomics study, we detected both S1008A and S1009A in nasal
lavage fluids from aCRS subjects [37]. This apparent discrepancy
might be explained by a compensatory increase in S100A8 and
S100A9 expression by a non-epithelial cell type, as suggested by
Tieu et al. [36], but this awaits further clarification.
Analysis of the differentially transcribed genes in aCRSwNP
using Ingenuity Pathway Analysis software identified disease-
associated networks related to inflammation (involving molecules
like NF-kB, IL6, TNF, and TGFb1), cell adhesion (ITGB2 and
ITGAM), and Th2-type cytokines (IL4 and IL13), and IL4R is
increased in both AD and aCRSwNP (Table 2). Interestingly, a
molecular network centered around the homodimer of PDGFB
(i.e. PDGFBB) included a series of genes showing decreased
transcription in aCRSwNP (Figure 4). Furthermore, several genes
within this network (MYH11, CNN1, FHL1), and several other
genes related to smooth muscle (ACTG2, DES, LMOD1,
MYRIP, PLN, and TAGLN), were also differentially transcribed
in AD (Table 2). How decreased transcription of these genes might
contribute to disease pathology is unclear. However, a PDGFRA
mutation was associated with Gleevac-sensitive hypereosinophilic
syndrome (HES), so perhaps decreased PDGFB-related transcrip-
tion is also associated with an eosinophilic response. Alternatively,
perhaps the epithelial hyperreactivity or altered vascular tone
common to eosinophilic diseases and involving smooth muscle
control are influenced by PDGFB-associated gene expression.
Regardless, our results are the first indication that decreased gene
expression of several smooth muscle-related genes associated with
PDGFB may be involved in the pathology of aCRSwNP and other
eosinophilic epithelial diseases.
In summary, exon array data for adjacent inflamed mucosa and
polyp tissue from aCRSwNP patients confirmed the differential
transcription of several genes that appear important in aspirin-
sensitive aCRSwNP [11]. It also identified several genes or gene
sets that likely contribute to the earlier stages of the eosinophilic
inflammation of aCRSwNP (Figure 5), and some of these genes are
also differentially transcribed in other eosinophilic epithelial
diseases, such as AD and EE. Overall, these data should assist in
the pursuit of improved treatments for aCRSwNP and other
eosinophilic diseases.
Supporting Information
Table S1 Nasosinus Tissue Donor Characteristics.
Found at: doi:10.1371/journal.pone.0011450.s001 (0.10 MB
DOC)
Table S2 Differentially Transcribed Genes in Asthmatic Chron-
ic Rhinosinusitis with Nasal Polyposis.
Found at: doi:10.1371/journal.pone.0011450.s002 (0.13 MB
XLS)
Figure S1 Molecular Network Implicating Nuclear Factor-
kappa B (NF-kB) in the Increased Transcription of aCRSwNP-
associated Chemokines/Chemokine Receptors and Other Genes.
The genes showing increased transcription in aCRSwNP (see
Table S2) were analyzed using Ingenuity Pathways Analysis
software, and this was the first-most significant network identified.
The intensity of red indicates the degree of increased transcription.
Found at: doi:10.1371/journal.pone.0011450.s003 (1.30 MB TIF)
Figure S2 Increased CD11c+ Cells in CRS with Nasal
Polyposis. Nasosinus tissue from a CRS patient with nasal polyps
Figure 5. Potential Relationship of Observed Gene Transcription Changes with Eosinophilic Inflammation. Three stimuli (Ascaris suum,
Dermatophagoides pteronyssinus (Der p), and Alternaria) associated with eosinophilic inflammation appear to induce one or more of the
Chromosome 17q11.2 eotaxin-1 (CCL11) or MCP genes [25,26]. Alternaria may induce this gene transcription via the IL33 – IL1RL1 interaction, and this
interaction appears to contribute to eosinophilic inflammation of human AD and aCRSwNP, in part via an NFkB-dependent mechanism [32]. In the
Th2-like milieu of AD and aCRSwNP, likely arising from an unfavorable mix of environmental exposures and genetic susceptibilities, alternatively-
activated monocyte-derived cells (aaMonocytes), such as ‘‘inflammatory DCs’’ [24], may develop and amplify the Th2-like eosinophilic response via
chemokine production. Other genes likely associated with Th2-like eosinophilic inflammation are also indicated. Items in bold are supported by our
array data. MC, mast cell; Baso, basophil; Eos, Eosinophil; DC, dendritic cells.
doi:10.1371/journal.pone.0011450.g005
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presence of CD11c is shown by reddish-brown staining.
Found at: doi:10.1371/journal.pone.0011450.s004 (5.71 MB TIF)
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